Successful management of refractory haematuria with recombinant porcine factor VIII replacement for paediatric congenital haemophilia A with high‐titre inhibitor

gait alterations in patients. In that case, sensor-based gait analysis could function as an objective measure to monitor recovery after a muscle or joint bleed, to evaluate prophylactic treatment and to substantiate physiotherapist exercises, something thus far impossible. In conclusion, sensor-based gait analysis is able to detect joint-specific arthropathy, specifically of the knee and hip in haemophilia patients. Compared to laborious conventional gait analysis, it is feasible and enables rapid, extensive gait analysis which can be performed during regular outpatient visits to the Haemophilia Treatment Centre.

[1]  E. Gomperts,et al.  Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  C. Kempton,et al.  Pharmacokinetics and safety of OBI‐1, a recombinant B domain‐deleted porcine factor VIII, in subjects with haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  E. Berntorp Importance of rapid bleeding control in haemophilia complicated by inhibitors , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  C. Négrier,et al.  Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  V. Toschi OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII. , 2010, Current opinion in molecular therapeutics.

[6]  E. Berntorp,et al.  Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  C. Kempton,et al.  A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII. , 2007 .

[8]  D. Dimichele,et al.  Inhibitor treatment in haemophilias A and B: inhibitor diagnosis , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  B. Evatt,et al.  Renal disease among males with haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  K. Evans,et al.  Renal abnormalities in patients with haemophilia and Christmas disease. , 1972, Clinical radiology.